Suchergebnisse - "Raymundo, Suziane"

PubPharm (17)

1

Determination of Endogenous Concentrations of Uracil and Dihydrouracil in Dried Saliva Spots by LC-MS/MS : Method Development, Validation, and Clinical Application

enthalten in: Therapeutic drug monitoring | 2019

von Antunes, M. | Raymundo, S. | Cezimbra da Silva, A. | +4

2

DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity

enthalten in: Clinical biochemistry | 2018

von Neto, O. | Raymundo, S. | Franzoi, M. | +8

3

Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry

enthalten in: Clinical biochemistry | 2018

von Andriguetti, N. | Hahn, R. | Lizot, L. | +8

4

Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel

enthalten in: Current medicinal chemistry | 2017

von Andriguetti, N. | Raymundo, S. | Antunes, M. | +4

5

Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel

enthalten in: Current medicinal chemistry | 2017

von Andriguetti, N. | Raymundo, S. | Antunes, M. | +4

6

Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies

enthalten in: Clinical biochemistry | 2016

von Galarza, A. | Linden, R. | Antunes, M. | +6

7

Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies

enthalten in: Clinical biochemistry | 2016

von Galarza, A. | Linden, R. | Antunes, M. | +6

8

Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies

enthalten in: Clinical biochemistry | 2016

von Galarza, A. | Linden, R. | Antunes, M. | +6

9

Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation

enthalten in: Therapeutic drug monitoring | 2015

von Antunes, M. | Timm, T. | de Oliveira, V. | +10

10

CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen

enthalten in: Pharmacogenomics | 2015

von Antunes, M. | de Oliveira, V. | Raymundo, S. | +10